Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 Via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty

Next Previous
Trial Profile

A Phase 2b, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 Via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine/meloxicam (Primary) ; Bupivacaine; Ropivacaine
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Heron Therapeutics

Most Recent Events

  • 05 Oct 2020 Results of pooled analysis of data pooled from 4 studies assessing the safety and plasma concentrations of various doses of HTX-011 in a variety of surgical sites with differing vascularity, presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists
  • 04 Jun 2020 According to the Heron Therapeutics media release, data from this study was published published online by The Journal of Arthroplasty.
  • 04 Jun 2020 Results published in the Heron Therapeutics media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top